Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on LinkedIn:
“Pancreatic cancer may be entering a new era.
Daraxonrasib receives rapid FDA expanded access in metastatic PDAC (approved in 2 days).
RASolute 302:
- OS: 13.2 vs 6.7 months
- 60% reduction in risk of death
Key questions:
- Will RASolute 303 reproduce this in the first-line setting?
- And more importantly:
- Will resistance to RAS(ON) inhibition be driven by EGFR rebound, or by pancreas-specific adaptive pathways?
The answer will likely be combination strategies.
Other Articles Featuring Ahmet Dirican On OncoDaily.